IP Library Granted Patent US 10,265,404
Granted Patent B2
US 10,265,404 · App. 14/078,746 · Granted Apr 23, 2019

Compositions, gels and foams with rheology modulators and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,265,404
App. No.
14/078,746
Granted
Apr 23, 2019
Kind
B2
Abstract

The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.

Claims (25)

1. An oleaginous foam composition comprising:

a) a combination of at least one fatty alcohol and at least one wax; or a combination of at least one fatty alcohol, at least one fatty acid, and at least one wax;

b) at least one hydrophobic solvent; and

c) a minocycline at a concentration between about 1% and about 4% by weight of the composition;

wherein the composition is free of surfactant;

wherein the composition is essentially waterless;

wherein the ratio of (1) fatty alcohol to wax or (2) fatty alcohol and fatty acid to wax is between about 1:3 and about 3:1; and

wherein the wax comprises a mixture of beeswax and hydrogenated castor oil.

2. The composition of claim 1 , wherein the minocycline is present in a free base form, a hydrate form, a salt form, or a complex form.

3. The composition of claim 1 , further comprising a tetracycline, an oxytetracycline, a demeclocycline, a doxycycline, a lymecycline, a meclocycline, a methacycline, a rolitetracycline, a chlorotetracycline, a tigecycline, or a mixture of two or more thereof.

4. The composition of claim 1 , further comprising a doxycycline.

5. The composition of claim 1 , wherein the concentration of the minocycline is about 4% by weight of the composition.

6. The composition of claim 1 , wherein the concentration of the minocycline is about 1% by weight of the composition.

7. The composition of claim 1 , wherein the at least one fatty alcohol comprises 14 carbon atoms in its backbone.

8. The composition of claim 1 , wherein the fatty alcohol comprises stearyl alcohol, cetostearyl alcohol, behenyl alcohol, and/or myristyl alcohol.

9. The composition of claim 1 , wherein the at least one fatty alcohol is present at a concentration from about 0.1% to about 20% by weight of the composition.

10. The composition of claim 1 , wherein the at least one wax and/or the at least one fatty acid is present at a concentration from about 0.1% to about 20% by weight of the composition.

11. The composition of claim 1 , wherein the hydrophobic solvent comprises soybean oil, coconut oil, cyclomethicone, and/or mineral oil.

12. The composition of claim 1 , wherein the hydrophobic solvent is present at a concentration from about 60% to about 95% by weight of the composition.

13. The composition of claim 1 , further comprising a retinoid.

14. The composition of claim 13 , wherein the retinoid comprises tazarotene, adapalene, and/or isotretinoin.

15. The composition of claim 1 , further comprising a silicon dioxide.

16. The composition of claim 1 , further comprising a benzoyl peroxide.

17. The composition of claim 1 , wherein the wax comprises a mixture of beeswax and hydrogenated castor oil at a ratio of about 1:1.

18. The composition of claim 1 , wherein the concentration of the minocycline is about 3% by weight of the composition.

Assignments (11)
SECURITY INTEREST Recorded Dec 28, 2023
From: JOURNEY MEDICAL CORPORATION; JG PHARMA, INC.
To: SWK FUNDING LLC
Reel/Frame 066157/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: VYNE THERAPEUTICS INC.; VYNE PHARMACEUTICALS INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 058925/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: VYNE THERAPEUTICS INC.
To: VYNE PHARMACEUTICALS INC.
Reel/Frame 058463/0208 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →
CHANGE OF NAME Recorded Jul 30, 2014
From: FOAMIX LTD.
To: FOAMIX PHARMACEUTICALS LTD.
Reel/Frame 033445/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2013
From: TAMARKIN, DOV; GAZAL, ELANA; HAZOT, YOHAN; SCHUZ, DAVID; PAPIASHVILI, IRAKLIY
To: FOAMIX LTD.
Reel/Frame 031706/0147 →
Cited By (1)
US 12,661,407